Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Marina Chiara Garassino(University of Chicago), Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hossein Borghaei(Fox Chase Cancer Center), Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shirish M. Gadgeel(Chinese University of Hong Kong), Bilal Piperdi(Université Toulouse III - Paul Sabatier), Ying Cheng(Jilin Province Tumor Hospital), Julie Kobie(Merck & Co., Inc., Rahway, NJ, USA (United States)), Silvia Novello(University of Turin), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew Albright(Merck & Co., Inc., Rahway, NJ, USA (United States)), Deepti Aurora-Garg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shunichi Sugawara(Sendai Kousei Hospital), Balázs Halmos(Montefiore Medical Center), Corey J. Langer(University of Pennsylvania), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rina Hui(The University of Sydney)
Cited by 105
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k